glp 1 agonist gastroparesis Drug-Induced and Product Liability GLP-1 Receptor Agonists in Gastrointestinal

Discover how once-monthly maridebart cafraglutide for the treatment of obesity works, its clinical trial evidence, potential eligibility criteria, side effects, and the pathway to NHS access if approved by UK regulators.

Learn how GLP-1s, GIPs, and newer combo drugs work, and whats currently FDA-approved.

Society guidelines have left clinicians with some questionable recommendations

BCBS dropped GLP-1 weight loss drug coverage across multiple states

Our sugar-free, lemon-flavored GLP-1 oral liquid formula can be mixed with water or taken sublingually

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron